Evidence map›Paper›PMID 42169260›Full record

ArticleJournal for immunotherapy of cancer2023

Novel treatments for novel side effects: a case report and review of baricitinib use in the treatment of chronic inflammatory demyelinating polyneuropathy caused by immune checkpoint inhibitor use.

Sana Haider, Wei Chua, Bavanthi Balakrishnar, Stephen Della-Fiorentina, Tara Laurine Roberts, Karuna Keat

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sana HaiderIngham Institute, Liverpool, New South Wales, Australia sana_haider@outlook.com.
Wei ChuaSchool of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.
Bavanthi BalakrishnarDepartment of Medical Oncology, Liverpool Hospital, Liverpool, New South Wales, Australia.
Stephen Della-FiorentinaImmunology and Allergy Unit, Department of Medicine, Campbelltown Hospital, Campbelltown, New South Wales, Australia.
Tara Laurine RobertsSchool of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.
Karuna KeatSchool of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) have transformed the landscape of solid cancer management. These drugs carry a risk of novel side effects, which have become known as immune-related adverse events (irAEs).Traditionally, irAEs have been managed empirically with corticosteroids. A subset of these may be steroid refractory and as more evidence emerges about their distinct pathogeneses, a more tailored approach is required. Here, we report the use of a Janus kinase (JAK) inhibitor, baricitinib, in a patient with chronic inflammatory demyelinating polyneuropathy secondary to ICI use. We also review the current literature with regards to the use of these inhibitors in the management of irAEs.Modulation of the JAK pathway warrants further investigation in the targeted management of irAEs.

Indexed as

Immune Checkpoint InhibitorsImmunotherapy

Identifiers

PMID42169260
PMCPMC10668263

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.